Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes

Biochemical Pharmacology

Volumn 50, Issue 3, 1995, Pages 287-297

  Hofland, Leo J ^a   Visser Wisselaar, Heleen A ^a   Lamberts, Steven W J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

binding; function; internalization; receptor subtype; somatostatin analog; tumor

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; RECEPTOR SUBTYPE; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; VAPREOTIDE;

DRUG SYNTHESIS; GLUCAGON RELEASE; HUMAN; INSULIN RELEASE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR CELL;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; HUMAN; MOLECULAR SEQUENCE DATA; NEOPLASMS; OCTREOTIDE; PEPTIDES, CYCLIC; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 0029089558     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)00066-9     Document Type: Article

References (99)

1. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro
2. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
3. N-terminally extended somatostatin: The primary structure of somatostatin-28
4. Processing of prosomatostatin
5. Somatostatin: Physiological and clinical significance
6. Depressant action of TRH, LH-RH and somatostatin on activity of central neurones
7. Is somatostatin an excitatory transmitter in the hippocampus?
8. Peptides in the brain: The new endocrinology of the neuron
9. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors
10. Long-term infusion of growth hormone release inhibiting hormone in acromegaly: Effects on pituitary and pancreatic hormones
11. Growth hormone release inhibiting hormone in acromegaly
12. The role of somatostatin and its analogs in the diagnosis and treatment of tumors
13. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
14. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin
15. Superactive octapeptide somatostatin analogues containing tryptophan at position 1
16. Somatostatin and somatostatin analogues in oncology
17. Differential binding of somatostatin agonists to somatostatin receptors in brain and adenohypophysis
18. Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications
19. In vitro detection of somatostatin receptors in human tumors
20. 3]-octreotide: The Rotterdam experience with more than 1000 patients
21. Evidence of two somatostatin-14 receptor types in rat brain cortex
22. New specific radioligand for one subpopulation of brain somatostatin receptors
23. Two types of somatostatin receptors differentiated by cyclic somatostatin analogs
24. Brain somatostatin receptor subpopulation visualized by autoradiography
25. Distinct topographical localization of two somatostatin receptor subpopulations in the human cortex
26. Differential effects of somatostatin on adenylate cyclase as functional correlate for different brain somatostatin receptor subpopulations
27. Evaluation of receptors for somatostatin in various tumors using different analogs
28. Biochemical and functional properties of somatostatin receptors
29. Evidence for multiple protein constituents of the somatostatin receptor in pituitary tumor cells: Affinity cross-linking and molecular characterization
30. Mechanism of action of somatostatin: An overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins
31. Purification of a pituitary receptor for somatostatin
32. Structural analysis and functional role of the carbohydrate component of somatostatin receptors
33. Expression of multiple somatostatin receptor genes in AtT-20 cells
34. Molecular heterogeneity of somatostatin analogue BIM-23014C receptors in human breast carcinoma cells using the chemical cross-linking assay
35. A cross-linking assay allows the detection of receptors for the somatostatin analogue, lanreotide in human breast tumours
36. functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype
37. Localization to human chromosomes 14, 17, and 22 and identification of simple tandem repeat polymorphisms
38. Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28
39. Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20.
40. A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides
41. Human somatostatin receptor genes: Localization of SSTR5 to human chromosome 20p11.2
42. Molecular cloning and functional expression of a brain-specific somatostatin receptor
43. Cloning and functional characterization of a novel somatostatin receptor, SSTR3, coupled to adenylyl cyclase
44. Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase
45. Pharmacological properties of two cloned somatostatin receptors
46. Characterization of cloned somatostatin receptors SSTR4 and SSTR5
47. Distribution and second messenger coupling of four somatostatin receptor subtypes expressed in brain
48. All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase
49. 2+ mobilization
50. 2+ mobilization by cloned human somatostatin receptor subtypes 1–5, in transfected COS-7 cells
51. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2
52. Cloned somatostatin receptors: Identification of subtypeselective peptides and demonstration of high affinity binding of linear peptides
53. Cloning and characterization of a fourth human somatostatin receptor
54. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors.
55. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro
56. Chronic somatostatin analog administration in patients with α-subunit-secreting pituitary tumors
57. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors
58. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interaction?
59. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization
60. Somatostatin receptor subtype gene expression in human and rodent tumors
61. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells
62. Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201995; Effects on cell cycle parameters and apoptotic cell death
63. Growth of human breast cancer cell lines is inhibited by the somatostatin analog BIM23014
64. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro
65. Antiproliferative effects of somatostatin and the somatostatin analog SMS 201995 on three human breast cancer cell lines
66. Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and sandostatin
67. Oncological applications of somatostatin analogues
68. Direct inhibitory effects of a somatostatin analog, SMS 201-995, on AR4-2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism
69. Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin
70. Dissociation of antiproliferative and antihormonal effects of the somatostatin analogue octreotide on 7315b pituitary tumor cells
71. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase
72. Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells
73. Characterization of 17-β-estradiol-dependent and -independent somatostatin receptor subtypes in rat anterior pituitary
74. 17β-Estradiol induces somatostatin (SRIF) inhibition of prolactin release and regulates SRIF receptors in rat anterior pituitary cells
75. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture
76. Mechanism of thyroid hormone inhibition of thyrotropin-releasing hormone action
77. Relationship between receptor binding and biopotency of somatostatin-14 and somatostatin-28 in mouse pituitary tumor cells
78. 1 pituitary cells and does not reduce cellular responsiveness to somatostatin
79. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160
80. A dual effect of somatostatin on the proliferation of cultured rat mesangial cells
81. Unexpected growth-stimulatory effect of somatostatin analogue on cultured human pancreatic carcinoid cells
82. Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth.
83. Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro
84. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells
85. Ultrastructural evidence for endogenous somatostatinlike immunoreactivity in the pituitary gland
86. Internalization and subcellular distribution of radiolabeled somatostatin-28 in mouse anterior pituitary tumor cells
87. Ultrastructural autoradiographic localization of somatostatin-28 in the rat anterior pituitary gland
88. Binding and internalization of somatostatin, insulin, and glucagon by cultured rat islet cells.
89. Internalization and cellular processing of somatostatin in primary cultures of rat anterior pituitary cells
90. Binding and internalization of gold-conjugated somatostatin and growth hormone-releasing hormone in cultured rat somatotropes
91. Somatostatin receptors are biologically active before they are inserted into the plasma membrane
92. Role of the secretion vesicle in the transport of receptors: Modulation of somatostatin binding to pancreatic islets
93. 1 rat pituitary cells
94. 11]somatostatin by RINm5F insulinoma cells
95. Localization of endocrine-related tumours with radioiodinated analogue of somatostatin
96. In vivo use of a radioiodinated somatostatin analogue: Dynamics, metabolism and binding to somatostatin receptor positive tumors in man
97. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide
98. 1]-octreotide: A case history
99. From receptor internalization to nuclear translocation